OS Therapies to Present at the LD Micro Main Event XVII

Rhea-AI Summary

OS Therapies (NYSE American: OSTX), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, has announced its participation in the LD Micro Main Event XVII. CEO Paul Romness and CBO Gerald Commissiong will deliver a corporate overview presentation on Tuesday, October 29, 2024, at 11:30 AM PT at the Luxe Sunset Boulevard Hotel in Los Angeles. The conference runs from October 28-30, 2024. Both executives will be available for one-on-one meetings with registered conference investors.

NEW YORK--(BUSINESS WIRE)-- OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announces that Paul Romness, Chief Executive Officer, and Gerald Commissiong, Chief Business Officer, will present a corporate overview at the LD Micro Main Event XVII. The conference is being held on October 28 – 30, 2024 at the Luxe Sunset Boulevard Hotel in Los Angeles.

Event:		LD Micro Main Event XVII
Presentation Date:		Tuesday, October 29, 2024
Time:		11:30 AM PT
Register to watch presentation:		https://me24.sequireevents.com/

Mr. Romness and Mr. Commissiong will be available for one-on-one meetings with registered investors of the conference.

About OS Therapies

OS Therapies is a clinical stage oncology company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company’s lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. The Company has completed enrollment for a 41-patient Phase 2b clinical trial of OST-HER2 in resected, recurrent osteosarcoma, with results expected in the fourth quarter of 2024. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing strong preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. In addition, OS Therapies is advancing its next generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company’s proprietary silicone linker technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those described under the section entitled "Risk Factors" of our Registration Statement on Form S-1 declared effective by the Securities and Exchange Commission (the "SEC") on July 31, 2024, as well as any of our periodic reports filed with the SEC, and that actual results may differ materially from those indicated by such forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241024219416/en/

Corporate and Media Contact:

Jack Doll

410-297-7793

irpr@ostherapies.com

Source: OS Therapies

FAQ

When is OS Therapies (OSTX) presenting at LD Micro Main Event XVII?

OS Therapies (OSTX) is presenting on Tuesday, October 29, 2024, at 11:30 AM PT during the LD Micro Main Event XVII conference.

Where is the LD Micro Main Event XVII featuring OS Therapies (OSTX) being held?

The LD Micro Main Event XVII is being held at the Luxe Sunset Boulevard Hotel in Los Angeles from October 28-30, 2024.

Who will represent OS Therapies (OSTX) at the LD Micro Main Event XVII?

CEO Paul Romness and Chief Business Officer Gerald Commissiong will represent OS Therapies (OSTX) at the event, presenting a corporate overview and conducting one-on-one meetings with registered investors.

Can investors meet with OS Therapies (OSTX) management at the LD Micro event?

Yes, registered investors of the conference can schedule one-on-one meetings with OS Therapies (OSTX) executives Paul Romness and Gerald Commissiong.